S&P 500   4,049.05 (+0.53%)
DOW   32,856.25 (+0.42%)
QQQ   315.52 (+0.90%)
AAPL   162.04 (+0.79%)
MSFT   283.80 (+1.17%)
META   207.61 (+1.10%)
GOOGL   100.91 (-0.47%)
AMZN   101.94 (+1.69%)
TSLA   195.71 (+0.94%)
NVDA   273.92 (+1.51%)
NIO   10.43 (+6.10%)
BABA   103.60 (+3.68%)
AMD   97.92 (+1.90%)
T   19.11 (+0.58%)
F   12.25 (+1.66%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.21%)
GE   94.03 (-0.03%)
DIS   98.03 (+1.20%)
AMC   4.90 (-2.00%)
PFE   40.32 (+0.17%)
PYPL   74.34 (+0.22%)
NFLX   339.42 (+2.23%)
S&P 500   4,049.05 (+0.53%)
DOW   32,856.25 (+0.42%)
QQQ   315.52 (+0.90%)
AAPL   162.04 (+0.79%)
MSFT   283.80 (+1.17%)
META   207.61 (+1.10%)
GOOGL   100.91 (-0.47%)
AMZN   101.94 (+1.69%)
TSLA   195.71 (+0.94%)
NVDA   273.92 (+1.51%)
NIO   10.43 (+6.10%)
BABA   103.60 (+3.68%)
AMD   97.92 (+1.90%)
T   19.11 (+0.58%)
F   12.25 (+1.66%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.21%)
GE   94.03 (-0.03%)
DIS   98.03 (+1.20%)
AMC   4.90 (-2.00%)
PFE   40.32 (+0.17%)
PYPL   74.34 (+0.22%)
NFLX   339.42 (+2.23%)
S&P 500   4,049.05 (+0.53%)
DOW   32,856.25 (+0.42%)
QQQ   315.52 (+0.90%)
AAPL   162.04 (+0.79%)
MSFT   283.80 (+1.17%)
META   207.61 (+1.10%)
GOOGL   100.91 (-0.47%)
AMZN   101.94 (+1.69%)
TSLA   195.71 (+0.94%)
NVDA   273.92 (+1.51%)
NIO   10.43 (+6.10%)
BABA   103.60 (+3.68%)
AMD   97.92 (+1.90%)
T   19.11 (+0.58%)
F   12.25 (+1.66%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.21%)
GE   94.03 (-0.03%)
DIS   98.03 (+1.20%)
AMC   4.90 (-2.00%)
PFE   40.32 (+0.17%)
PYPL   74.34 (+0.22%)
NFLX   339.42 (+2.23%)
S&P 500   4,049.05 (+0.53%)
DOW   32,856.25 (+0.42%)
QQQ   315.52 (+0.90%)
AAPL   162.04 (+0.79%)
MSFT   283.80 (+1.17%)
META   207.61 (+1.10%)
GOOGL   100.91 (-0.47%)
AMZN   101.94 (+1.69%)
TSLA   195.71 (+0.94%)
NVDA   273.92 (+1.51%)
NIO   10.43 (+6.10%)
BABA   103.60 (+3.68%)
AMD   97.92 (+1.90%)
T   19.11 (+0.58%)
F   12.25 (+1.66%)
MU   62.80 (-1.16%)
CGC   1.77 (-2.21%)
GE   94.03 (-0.03%)
DIS   98.03 (+1.20%)
AMC   4.90 (-2.00%)
PFE   40.32 (+0.17%)
PYPL   74.34 (+0.22%)
NFLX   339.42 (+2.23%)
NASDAQ:AGEN

Agenus - AGEN Stock Forecast, Price & News

$1.49
-0.07 (-4.49%)
(As of 03/30/2023 03:52 PM ET)
Add
Compare
Today's Range
$1.45
$1.61
50-Day Range
$1.48
$2.77
52-Week Range
$1.25
$3.37
Volume
2.19 million shs
Average Volume
4.78 million shs
Market Capitalization
$495.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Agenus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
393.3% Upside
$7.33 Price Target
Short Interest
Bearish
6.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.09mentions of Agenus in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.87) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

557th out of 999 stocks

Biological Products, Except Diagnostic Industry

93rd out of 166 stocks


AGEN stock logo

About Agenus (NASDAQ:AGEN) Stock

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Stock News Headlines

Agenus (NASDAQ:AGEN) Stock Price Up 5.7%
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Why Agenus Stock Is Slumping This Week
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Agenus Stock (NASDAQ:AGEN), Dividends
Agenus to Participate in February Investor Conferences
Agenus' Updated Data Confirms Long-Term Potential Value
2 Momentum Trades Showing Worst to First Action
Agenus: Perpetually Getting There
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Company Calendar

Last Earnings
11/09/2021
Today
3/30/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
441
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$8.30
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-220,070,000.00
Net Margins
-235.30%
Pretax Margin
-235.31%

Debt

Sales & Book Value

Annual Sales
$98.02 million
Book Value
($0.18) per share

Miscellaneous

Free Float
316,552,000
Market Cap
$487.13 million
Optionable
Optionable
Beta
1.50

Key Executives

  • Garo H. ArmenGaro H. Armen
    Chairman & Chief Executive Officer
  • Christine M. Klaskin
    Chief Financial & Accounting Officer, VP-Finance
  • Steven O’DaySteven O’Day
    Chief Medical Officer
  • Craig Winter
    Chief Information Officer
  • Alfred Dadson
    Chief Manufacturing Officer













AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month price objectives for Agenus' shares. Their AGEN share price forecasts range from $5.00 to $8.30. On average, they anticipate the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2023?

Agenus' stock was trading at $2.40 at the start of the year. Since then, AGEN shares have decreased by 39.0% and is now trading at $1.4650.
View the best growth stocks for 2023 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) posted its earnings results on Tuesday, November, 9th. The biotechnology company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.23. The biotechnology company had revenue of $252.95 million for the quarter, compared to analysts' expectations of $183.11 million. Agenus had a negative trailing twelve-month return on equity of 1,159.04% and a negative net margin of 235.30%. During the same quarter in the previous year, the firm earned ($0.28) earnings per share.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (4.76%), Point72 Asset Management L.P. (2.93%), Geode Capital Management LLC (1.72%), Renaissance Technologies LLC (1.27%), Charles Schwab Investment Management Inc. (0.69%) and Lindbrook Capital LLC (0.44%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.47.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $487.13 million and generates $98.02 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Agenus have?

The company employs 441 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 3/30/2023 by MarketBeat.com Staff